<ARTICLE> 5 <LEGEND> This schedule contains summary financial information extracted from the Condensed Consolidated Statement of Operations for the Three Months Ended September 30, 2000 and the Condensed Consolidated Statement of Financial Position at September 30, 2000 and is qualified in its entirety by reference to such financial statements. </LEGEND> <MULTIPLIER> 1,000 <PERIOD-TYPE> 3-Mos <FISCAL-YEAR-END> Jun-30-2001 <PERIOD-START> Jul-01-2000 <PERIOD-END> Sep-30-2000 <CASH> 844,270 <SECURITIES> 540,745 <RECEIVABLES> 362,310 <ALLOWANCES> 4,338 <INVENTORY> 158,769 <CURRENT-ASSETS> 1,992,752 <PP&E> 593,529 <DEPRECIATION> 199,099 <TOTAL-ASSETS> 2,985,787 <CURRENT-LIABILITIES> 564,972 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 2,704 <OTHER-SE> 2,239,484 <TOTAL-LIABILITY-AND-EQUITY> 2,985,787 <SALES> 367,414 <TOTAL-REVENUES> 367,414 <CGS> 163,501 <TOTAL-COSTS> 163,501 <OTHER-EXPENSES> 0 <LOSS-PROVISION> 440 <INTEREST-EXPENSE> 1,053 <INCOME-PRETAX> 36,736 <INCOME-TAX> 12,280 <INCOME-CONTINUING> 24,456 <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> 24,456 <EPS-BASIC> 0<F1> <EPS-DILUTED> 0<F2> <FN> <F1>Basic earnings per share - PE Biosystems Group .23 Basic loss per share - Celera Genomics Group (.43) <F2>Diluted earnings per share - PE Biosystems Group .22 Diluted loss per share - Celera Genomics Group (.43) </FN>